Market Overview

UPDATE: Merck Upgraded by Morgan Stanley on Oncology Optimism

Related MRK
Barclays' Biopharmaceuticals Blueprint For 2016
Barclays On Merck: Too Much Underlying Value To Ignore
Dividend Champions For December 2015 (Seeking Alpha)

In a report released Monday, JP Morgan analyst David Risinger upgraded Merck (NYSE: MRK) from Underweight to Overweight with a price target of $60.

Risinger notes, "Mgmt is taking the right steps—cost cuts, R&D changes, and considering strategic action—to boost company's outlook." One of the driving catalysts that the report mentioned is MK-3475, an immuno-oncology candidate which Merck filed for approval a year earlier than expected.

MRK closed Friday at $51.98 and is currently up nearly 3% at the $53.37 level.

Latest Ratings for MRK

Dec 2015BarclaysUpgradesEqual-weightOverweight
Nov 2015BerenbergInitiates Coverage onBuy
Sep 2015JP MorganMaintainsOverweight

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: News Upgrades Price Target Markets Analyst Ratings


Related Articles (MRK)

View Comments and Join the Discussion!

Get Benzinga's Newsletters